SCHEMBL11620522

SCHEMBL11620522

c1ccc2c(c1)CC(N1CCCCC1)C2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.59
GRIN2B Q13224 4/20 0.58
SIGMAR1 Q99720 1/20 0.50
HTR1A P08908 2/20 0.47
HTR7 P34969 1/20 0.47
ALDH1A1 P00352 3/20 0.47
TSHR P16473 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
L3MBTL3 Q96JM7 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MBTD1 Q05BQ5 1/20 0.47
KDM4E B2RXH2 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
PMP22 Q01453 1/20 0.45
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14876096 0.98 GRIN2B (0.60) FYNGRIN2BSIGMAR1HTR1AHTR7
SCHEMBL29447414 0.98 GRIN2B (0.60) FYNGRIN2BSIGMAR1HTR1AHTR7
SCHEMBL7436031 0.86 GRIN2B (0.66) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL9018525 0.86 GRIN2B (0.66) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL9506641 0.86 GRIN2B (0.66) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL9947164 0.86 GRIN2B (0.66) GRIN2BHTR1AHTR7TSHRLMNA
Hydrochloric Acid SCHEMBL7938970 0.85 GRIN2B (0.64) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL8673995 0.84 GRIN2B (0.68) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL9947176 0.84 GRIN2B (0.68) GRIN2BHTR1AHTR7TSHRLMNA
SCHEMBL3556300 0.81 GRIN2B (0.49) FYNGRIN2BHTR1AHTR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210186953-A1 NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2021-06-24 US disclosed
EP-2887964-B1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2019-07-03 EP disclosed
US-4127578-A Diene intermediates for indantetrols E. R. SQUIBB & SONS, INC. (US) 1978-11-28 US disclosed
US-4092318-A HYPOTENSIVES E. R. SQUIBB & SONS, INC. (US) 1978-05-30 US disclosed
US-4044040-A HYPERTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186953-A1 NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A3, SLC34A2, SLC34A1 FYN 4071/4885GRIN2B 3117/4885SIGMAR1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.